Law360, New York (August 08, 2006, 12:00 AM ET) -- Much to the horror of Bristol-Myers Squibb and Sanofi-Aventis, Apotex officially launched an at-risk generic version of Plavix on Tuesday after the settlement between the three companies over the patent failed to receive antitrust clearance.
“We are confident that the patent will be held invalid and that the courts will find inequitable conduct before the patent office on the part of Sanofi,” said Apotex Chief Executive Officer Dr. Barry Sherman. “Accordingly, Apotex has launched prior to trial so that patients and public and private health care...
Apotex Launches At-Risk Generic Plavix
To view the full article, take a free trial now.
